Acadia Pharmaceuticals is showcasing Daybue at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
They'll have it at the booth but it's secondary to Nuplazid for this audience. Rett syndrome is primarily managed by neurologists and developmental specialists, though psychiatrists may see behavioral symptoms. New STIX powder formulation (Dec 2025) launching broadly Q2 2026.
Ask about: New STIX formulation launch trajectory; how psychiatrists encounter Rett syndrome behavioral symptoms; caregiver support programs. Lower priority conversation at APA unless the attendee specifically works with developmental disorders.
ePRO+ video-based caregiver assessments capture Rett syndrome behavioral changes more richly than standard scales — especially valuable for the new STIX formulation adherence monitoring. Not the primary APA conversation but worth mentioning for completeness.
Set up a follow-up with Acadia Pharmaceuticals's team and Videra Health.
Email Ryan Roberts →